Pre-market: ALCJ.PA Crossject SA down 6.26% before 25 Mar 2026 earnings: catalysts

ALCJ.PA stock trades at €2.02 in pre-market, down 6.26%, as investors position ahead of Crossject SA’s earnings on 25 Mar 2026. Volume is elevated at 311,633 shares versus an average of 265,239, showing higher attention. Crossject (EURONEXT, Europe) will report results that could shift sentiment for its ZENEO needle-free injector pipeline and guide near-term cash needs.

Earnings timing and what matters

Crossject (ALCJ.PA stock) has an earnings announcement set for 25 Mar 2026. Investors will watch commentary on commercial traction for ZENEO, regulatory timelines, and cash burn. Management guidance on partnerships or contract wins will likely move the stock.

Recent price and financial snapshot

Price is €2.02, open €2.12, day low €2.00, day high €2.12, market cap €105,778,678, and shares outstanding 52,495,622. Trailing EPS is -0.22 and reported P/E is -9.16, reflecting losses. The 50-day average is €2.05 and the 200-day average is €1.97, so the stock sits near short-term trend levels.

Meyka Grade and technical view

Meyka AI rates ALCJ.PA with a score out of 100: 69.52 (B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show neutral momentum: RSI 48.53, MACD near zero, and Bollinger Bands €1.89–€2.21, signalling limited trend conviction. These grades are not guaranteed and we are not financial advisors.

Valuation, forecasts and price targets

Meyka AI’s forecast model projects a quarterly price of €1.88 and a yearly price of €1.28. Versus the current €2.02, the quarterly forecast implies -6.93% downside and the yearly forecast implies -36.84% downside. For scenario planning we offer analyst-style price targets: conservative €1.50, base €2.50, optimistic €3.20. Forecasts are model-based projections and not guarantees.

Sector context and comparables

ALCJ.PA stock sits in Healthcare, Medical – Instruments & Supplies, where sector average P/E is ~29.62. Crossject trades at a negative PE and smaller market cap versus peers, reflecting clinical-stage risk and limited sales. See competitor comparison for context on trading multiples and peers source.

Risks, catalysts and trading considerations

Key risks: ongoing net losses, negative EPS, and funding needs given operating cash flow per share -0.05 and free cash flow per share -0.07. Catalysts: positive regulatory updates, new commercial contracts for ZENEO, or partnership deals. For traders, watch pre-market flows, earnings commentary, and volume spikes; liquidity is modest with average volume 265,239.

Final Thoughts

ALCJ.PA stock opens the pre-market at €2.02 with elevated volume and a clear earnings event on 25 Mar 2026 that can swing sentiment. Fundamentals show a small market cap €105,778,678, negative EPS -0.22, and mixed cash metrics: cash per share €0.13 and current ratio 2.70, which provide some short-term cushion. Meyka AI’s model projects a quarterly guide of €1.88 and a yearly projection of €1.28, implying downside of -6.93% and -36.84% respectively versus today. We present conservative, base and optimistic price targets at €1.50 / €2.50 / €3.20 to frame scenarios. Monitor earnings detail on revenue recognition, cash runway signals, and regulatory notes. This article uses Meyka AI as an AI-powered market analysis platform and combines model forecasts with sector context; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.